Aptus Capital Advisors LLC Grows Position in iShares Biotechnology ETF $IBB

Aptus Capital Advisors LLC grew its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 9,664.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 204,362 shares of the financial services provider’s stock after buying an additional 202,269 shares during the period. Aptus Capital Advisors LLC owned 0.42% of iShares Biotechnology ETF worth $34,490,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of IBB. Citigroup Inc. increased its position in iShares Biotechnology ETF by 40.9% during the fourth quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock worth $884,808,000 after buying an additional 1,521,992 shares in the last quarter. BNP Paribas Financial Markets increased its position in iShares Biotechnology ETF by 313.2% during the third quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock worth $276,526,000 after buying an additional 1,451,820 shares in the last quarter. WestEnd Advisors LLC purchased a new position in iShares Biotechnology ETF during the fourth quarter worth $106,276,000. Truist Financial Corp increased its position in iShares Biotechnology ETF by 2,239.6% during the fourth quarter. Truist Financial Corp now owns 642,023 shares of the financial services provider’s stock worth $108,354,000 after buying an additional 614,582 shares in the last quarter. Finally, LPL Financial LLC increased its position in iShares Biotechnology ETF by 145.9% during the fourth quarter. LPL Financial LLC now owns 992,799 shares of the financial services provider’s stock worth $167,555,000 after buying an additional 589,033 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock opened at $170.66 on Friday. The stock has a fifty day moving average of $170.28 and a two-hundred day moving average of $170.65. iShares Biotechnology ETF has a fifty-two week low of $123.61 and a fifty-two week high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 20th. Stockholders of record on Tuesday, March 17th were issued a dividend of $0.1218 per share. The ex-dividend date was Tuesday, March 17th. This represents a $0.49 annualized dividend and a dividend yield of 0.3%.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.